Centocor subpoenaed
Executive Summary
The U.S. Attorney's office in California issues a subpoena to Johnson & Johnson subsidiary Centocor over an investigation into the average selling price calculations for Remicade (infliximab) under Centocor's "Contract Purchase Program." J&J discloses the information about the subpoena, which was issued Nov. 27, 2006, in its annual report Feb. 22. Remicade garnered $3.01 billion in 2006 sales, up 19 percent from 2005...